MX2022006861A - Agonistas del receptor glp2 y metodos de uso. - Google Patents

Agonistas del receptor glp2 y metodos de uso.

Info

Publication number
MX2022006861A
MX2022006861A MX2022006861A MX2022006861A MX2022006861A MX 2022006861 A MX2022006861 A MX 2022006861A MX 2022006861 A MX2022006861 A MX 2022006861A MX 2022006861 A MX2022006861 A MX 2022006861A MX 2022006861 A MX2022006861 A MX 2022006861A
Authority
MX
Mexico
Prior art keywords
methods
receptor agonists
glp
glp2
glp2 receptor
Prior art date
Application number
MX2022006861A
Other languages
English (en)
Inventor
Peter G Schultz
Weijun Shen
Zaid Amso
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of MX2022006861A publication Critical patent/MX2022006861A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan conjugados peptídicos que comprenden un péptido que modula el receptor GLP-2. Los conjugados peptídicos se pueden usar para tratar afecciones sensibles a la modulación del receptor GLP-2. Además, se proporcionan conjugados peptídicos de GLP-2 engrapados.
MX2022006861A 2019-12-04 2020-12-03 Agonistas del receptor glp2 y metodos de uso. MX2022006861A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962943667P 2019-12-04 2019-12-04
US202062994791P 2020-03-25 2020-03-25
PCT/US2020/063130 WO2021113524A2 (en) 2019-12-04 2020-12-03 Glp2 receptor agonists and methods of use

Publications (1)

Publication Number Publication Date
MX2022006861A true MX2022006861A (es) 2022-07-11

Family

ID=76222285

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022006861A MX2022006861A (es) 2019-12-04 2020-12-03 Agonistas del receptor glp2 y metodos de uso.
MX2022006732A MX2022006732A (es) 2019-12-04 2020-12-03 Conjugados peptidicos y metodos de uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022006732A MX2022006732A (es) 2019-12-04 2020-12-03 Conjugados peptidicos y metodos de uso.

Country Status (10)

Country Link
US (2) US20230057847A1 (es)
EP (2) EP4069726A4 (es)
JP (2) JP2023504184A (es)
KR (2) KR20220123648A (es)
CN (2) CN115052615A (es)
AU (2) AU2020397917A1 (es)
CA (2) CA3163507A1 (es)
IL (2) IL293460A (es)
MX (2) MX2022006861A (es)
WO (2) WO2021113524A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293460A (en) * 2019-12-04 2022-07-01 Scripps Research Inst 2glp receptor agonists and methods of using them
WO2023207106A1 (zh) * 2022-04-29 2023-11-02 苏州星洲生物科技有限公司 Glp-1/gip受体共激动剂、包含其的药物组合物及其用途
CN114949183B (zh) * 2022-05-07 2023-02-28 山东京卫制药有限公司 一种替尔泊肽粉雾剂及其制备方法
TW202410918A (zh) * 2022-05-27 2024-03-16 韓商Ｄ＆Ｄ製藥科技股份有限公司 用於治療神經病症之組合物及方法
US20240247080A1 (en) * 2022-12-21 2024-07-25 Boehringer Ingelheim International Gmbh Glp1/gip/npy2 receptor triple agonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9296805B2 (en) * 2009-06-18 2016-03-29 Dana-Farber Cancer Institute, Inc. Stabilized insulinotropic peptides and methods of use
BR112015027528B1 (pt) * 2013-05-02 2023-02-14 Glaxosmithkline Intellectual Property Development Limited Polipeptídeo, forma de sal, combinação farmacêutica e composição farmacêutica
JP6572497B2 (ja) * 2013-12-18 2019-09-11 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、ステープル留めされたペプチド脂質複合体、及びそれらの組成物
US20190000928A1 (en) * 2015-06-17 2019-01-03 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
CA3097104A1 (en) * 2018-04-19 2019-10-24 Stichting Vu Protein macrocyclization
IL293460A (en) * 2019-12-04 2022-07-01 Scripps Research Inst 2glp receptor agonists and methods of using them

Also Published As

Publication number Publication date
WO2021113535A1 (en) 2021-06-10
EP4069274A4 (en) 2024-04-10
IL293460A (en) 2022-07-01
WO2021113524A2 (en) 2021-06-10
CA3163522A1 (en) 2021-06-10
CN115052886A (zh) 2022-09-13
JP2023513658A (ja) 2023-04-03
IL293522A (en) 2022-08-01
US20230071371A1 (en) 2023-03-09
AU2020397917A1 (en) 2022-06-23
JP2023504184A (ja) 2023-02-01
CN115052615A (zh) 2022-09-13
EP4069726A4 (en) 2024-03-20
AU2020397918A1 (en) 2022-06-23
KR20220123648A (ko) 2022-09-08
WO2021113524A3 (en) 2021-07-15
US20230057847A1 (en) 2023-02-23
EP4069274A1 (en) 2022-10-12
EP4069726A2 (en) 2022-10-12
CA3163507A1 (en) 2021-06-10
MX2022006732A (es) 2022-08-19
KR20220110244A (ko) 2022-08-05

Similar Documents

Publication Publication Date Title
MX2022006861A (es) Agonistas del receptor glp2 y metodos de uso.
PH12020551144A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2021003393A (es) Proteinas de fijacion a sirp alfa y metodos de uso de estas.
CR20220178A (es) Compuestos moduladores de glp-1r
PH12020500398A1 (en) Antibody-pyrrolobenzodiazepine derivative conjugate
PH12020551140A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019550147A1 (en) Engineered transferrin receptor binding polypeptides
MX2019001223A (es) Moduladores de receptores de quimioquina y usos de los mismos.
MX2019014539A (es) Agentes multibioticos y metodos para utilizarlos.
MX2020007812A (es) Moduladores del receptor de quimiocina y usos de los mismos.
MX2021008334A (es) Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-farmaco.
PH12016501680A1 (en) Anti-egfrviii antibodies and uses thereof
UY37589A (es) COMPUESTOS MODULADORES DEL RECEPTOR DE HIDROCARBUROS ARÍLICOS (AhR)
UY37590A (es) COMPUESTOS MODULADORES DEL RECEPTOR DE HIDROCARBUROS ARÍLICOS (AhR)
MX2020010881A (es) Construcciones de anticuerpos anti-ror.
MX2021013417A (es) Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
WO2018136620A3 (en) Endosomal cleavable linkers
MX2022001146A (es) Formulaciones de anticuerpos anti-pvrig y sus usos.
MX2021002616A (es) Anticuerpos agonistas anti receptor desencadenante expresado en celulas mieloides 2 (trem-2).
MX2020002435A (es) Agentes que modulan las funciones de beta-catenina y sus métodos.
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
PH12021550289A1 (en) Ox40-binding polypeptides and uses thereof
MX2021013416A (es) Polipeptidos de union al antigeno cd33 y sus usos.
MX2021009993A (es) Metodos y dispositivos para localizar composiciones.
MX2021005874A (es) Anticuerpo que comprende una extension c-terminal de cadena ligera que contiene glutamina, conjugados del mismo y metodos y usos.